Cannabis Use Associated With Improved Outcomes In Bipolar Patients

MASSACHUSETTS: Cannabis use is associated with an alleviation of clinical symptoms in patients with bipolar disorder, and does not negatively impact cognitive performance, according to clinical trial data published in the journal PLoS One.

Investigators with Harvard Medical School, Tufts University, and McLean Hospital in Massachusetts assessed the impact of marijuana use on mood symptomology and cognitive function in patients with bipolar disorder.

Authors reported that marijuana use was associated with lower scores of anger, tension, and depression, as well as higher levels of vigor in BPD patients. Subjects who used marijuana also showed no significant differences in cognitive performance compared to BPD subjects who abstained from the plant. The study is the first clinical trial to assess the impact of cannabis on both mood and neuropsychological performance in BPD patients.

Researchers concluded, “The current study highlights preliminary evidence that patients with BPD who regularly smoked marijuana reported at least short-term clinical symptom alleviation following marijuana use, indicating potential mood-stabilizing properties of marijuana in at least a subset of patients with BPD.”


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “A pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood,” appears in PLoS One.

Maryland Medical Cannabis Forum Is Thursday, November 8, 2018

Presents an In-Depth Discussion of MMJ Research and Practice

MARYLAND – Maryland doctors can enhance their knowledge about medical cannabis treatment at the inaugural Maryland Medical Cannabis Forum (MMCF), on Thursday, November 8th in Baltimore.  The MMCF was created to provide to the Maryland medical community current and credible information on the state of medical cannabis research and practices–and how it affects the 35,000-and-growing Maryland MMJ patients. Discussion topics for the evening include:

  • The endocannabinoid system and its relation to treating diseases
  • Cancer case studies utilizing cannabis for symptom relief and pain management
  • Cannabis treatment for neurological disorders such as Alzheimer’s, epilepsy and autism
  • Cannabis and reduction in opioid dependency and other prescription medications
  • Proper dosing and understanding common side effects

The evening kicks off at 5:00 p.m. with a cocktail and hors d’oeuvres reception. The program begins at 6:30 p.m. with featured speakers Dr. Jokūbas Žiburkus (Canntelligence) and Dr. Dustin Sulak (Healer.com), followed by a panel discussion hosted by CNBC’s Tim Seymour and including Sid Taubenfeld of Tikun Olam’s TO Pharma and Joy Strand, Executive Director of the Maryland Medical Cannabis Commission, among others.

The MMCF is proud to have the support of MedChi (the Maryland State Medical Society), and sponsors including global medical cannabis brand Tikun Olam, MariMed Advisors and Kind Therapeutics to establish this event as a comprehensive and trustworthy forum for up-to-date information on medical cannabis for Maryland doctors to provide their patients. The registration fee for MMCF is $75, $50 for MedChi members; visit www.medicalcannabisforum.org.

Thousands Of Peer-Reviewed Studies Specific To Medical Cannabis Have Been Published Over Past Decade

ISRAEL: The total number of peer-reviewed scientific papers dedicated to cannabis, and the therapeutic use of cannabis in particular, has increased exponentially in recent years, according to data published the journal Population Health Management.

Israeli researchers assessed trends in the number of scientific publications specific to cannabis as compared to all scientific publications during the years 2000 to 2017. They reported: “The overall annual number of scientific publications … increased 2.5 times between 2000–2017 from 531,664 to 1,282,229. In contrast, the corresponding number for publications on cannabis increased 4.5 times … and increased 9-fold for publications on medical cannabis.”

Overall, authors identified just over 29,000 cannabis-centric scientific papers published during the study period, with over 3,300 of those dedicated to the subject of medical marijuana. Papers specific to medical cannabis were most likely to address its use in the treatment of HIV, chronic pain, multiple sclerosis, nausea, or epilepsy.

Over 60 percent of the papers were classified as “original research,” and 66 percent of all scientific papers originated from authors in the United States.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Trends in publications in medical cannabis from the year 2000,” appears in Population Health Management.

Study: Marijuana Use Associated With Lower Diabetes Risk

CANADA: The past use of cannabis is significantly associated with lower odds of diabetes in adults, according to data published in the journal Drug and Alcohol Review.

Investigators with the University of Toronto assessed the association between cannabis use and diabetes in a nationally representative sample, while accounting for a range of potential confounders – including lifestyle behaviors, socio-demographics, and mental health disorders.

Compared to non-users, subjects with a history of cannabis use possessed an approximately 20 percent decreased likelihood of diabetes. Those subjects with past-year marijuana use possessed an approximately 50 percent decreased risk.

“In sum, a decreased likelihood of diabetes for both lifetime and 12-month cannabis users versus non-users was found after accounting for a range of potential confounders, including mental health disorders,” authors concluded.

Although authors cautioned that “additional epidemiological studies … are needed before protective effects of cannabis can be suggested,” the study is one of several population studies identifying a positive association between lifetime cannabis consumption and a reduced risk for diabetes.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “The relationship between cannabis use and diabetes: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III,” appears in Drug and Alcohol Review. Additional information on the association between cannabis and diabetes is available online from NORML.

 

War Veteran Non-Profit Hosts Inaugural Medical Cannabis Conference Days Before Missourians Vote on Medical Cannabis Ballot

Nation’s Cannabis Experts Address Consumers, Healthcare Providers & Emerging Trade at October 27 & 28 St. Charles-based Forum

MISSOURI: The inaugural Missouri Medical Cannabis Conference will be held Saturday & Sunday, October 27 and October 28, and will provide voters, potential patients, caretakers, varied healthcare providers and those interested in the associated business and trade of medical cannabis broad access to experts and expert resources.

The event features medical cannabis healthcare providers, researchers and patients, as well as renowned leaders in various aspects of America’s medical cannabis movement.  Conference activities include keynote speeches, panel discussions, networking sessions and multiple food-based hospitality events.  The cost of attendance begins at $75; additional higher priced attendance packages are offered, with cost based on extent of conference access, special events and amenities included.

Held in St. Charles at the Embassy Suites by Hilton, conference organizers have structured Saturday’s session to focus on patient and healthcare subjects.  Sunday’s conference addresses the medical cannabis trade landscape and emerging business opportunities.  Saturday activities begin at 9 am, Sunday sessions begin at noon.   For a complete schedule, speaker information & pricing options, visit www.mocannacon.com

Screenshot 2018-10-18 09.22.48HOSTED BY WHO & WHY

The conference is organized and hosted by Missouri based Project 4-22 Foundation, a volunteer community initiative committed to mitigating the American military veteran suicide epidemic by seeking safer treatment options while raising awareness of the staggering death rates reported by the US Department of Veterans Affairs.

Project 4-22 organized this informative and educational forum with broad appeal to various constituents — from voters to healthcare providers — in advance of Missouri’s medical cannabis vote because every day at least 22 veterans commit suicide. With diagnoses ranging from post-traumatic stress to traumatic brain injury, veterans face limited and inadequate treatment that includes addictive opiates.  In November Missouri voters will make history, passing judgement on three separate medical cannabis initiatives on the ballot.  Project 4-22 advocates the medical benefits of cannabis and its use as an effective treatment for many veteran diagnoses, and designed the conference as an opportunity for Missourians to educate themselves before voting in November’s historical election.

MedPharm Awarded Colorado’s First Cannabis Research License

COLORADO:  MedPharm, a leading medical cannabis grow, R&D laboratory and compounding facility, announced today that it has been awarded the first cannabis research license by the state of Colorado. To get the license, the state looked at the applicant’s capabilities to successfully develop and conduct research.

The cannabis research license was created by the state to allow cannabis-related operators and researchers to study the plant and better understand what it offers. The application for the license included outlining research objectives and creating areas where medical research cannabis is grown specifically for research purposes.

“We have a strong research team of some of the best and brightest in the industry, and this cannabis research license will really help us in our quest to be a world leader in dosage formulation and product development,” Albert Gutierrez, CEO of MedPharm, says. “We are eager to look at what benefits the plant might offer for improving the human condition.”

Dr. Tyrell Towle, the director of chemistry for MedPharm with a PhD in medicinal and natural products chemistry, says that the cannabis research license will enable MedPharm to provide their high-quality dosage forms directly to study patients. “It will also allow us to perform Randomized Controlled Trials (RCTs) because we can supply placebos as well, which wasn’t previously allowed for,” he says. “We are now in a better position than any cannabis company to take on research partnerships and we welcome those who are interested in such partnerships.”

MedPharm currently makes three brands: Aliviar, a medically-focused brand that produces pharmaceutical grade dosage forms (www.aliviaralleviates.com); Become products for a mellow, balanced or elevated feeling (www.becomelifestyle.com); and Batch, an oil concentrate with higher percentages of THC for the cannabis connoisseur (www.batchextracts.com). “Our recent review of our strains shows a very rare and unique cannabinoid that we originally dismissed as interference. We were able to identify the cannabinoid and see its molecular structure, which is exciting,” Towle says.

Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Preliminary findings showed +80% of patients had increase in appetite and 60% +10% weight increase

ISRAEL & MARYLAND: Cannabics Pharmaceuticals, a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients.

Cannabics PharmaceuticalsHeld at Rambam Hospital in Israel, the study is aimed at evaluating the effect of dosage-controlled cannabis capsules on CACS, and more specifically, on weight variations in advanced cancer patients.

Preliminary findings showed that all patients who were involved in the study for the first four and a half months reported an increase in appetite, as well as 83 percent of all those that completed the study. Results also demonstrated a weight increase of over 10 percent for 60 percent of the patients who completed the study. The remaining patients had a stable weight. 50 percent of the patients who completed the study reported pain reduction and sleep improvement.

“Our first clinical trial, led by Dr. Gil Bar-Sela, gave us valuable data on the capsules as a possible oral administration method for palliative care and for our future proprietary cannabinoid compounds,” said Dr. Eyal Ballan, co-founder and chief technology officer of Cannabics Pharmaceuticals. “As we continue to progress in the development of personalized cannabinoid treatments and collect data on compounds, ratios and dosages, we will use the information to incorporate into the design of our next clinical study on cancer patients.”

 

Study: Adjunctive Cannabis Use Improves Treatment Retention In Opioid-Dependent Subjects

MISSOURI: The intermittent use of cannabis can play a positive role in opioid-dependent subjects undergoing treatment, according to a review published in the journal Cannabis and Cannabinoid Research.

Researchers from the Washington University School of Medicine in St. Louis assessed data evaluating the relationship between the use of cannabis and opioids.

They reported, “Adjunct cannabis use alongside current treatment strategies could help to improve the number of individuals engaging in OUD (opioid use disorder) treatment, as well as increase treatment retention rates.”

Specifically, authors acknowledged that the use of CBD is associated with reduced opioids cravings and relapse, and that cannabis acts synergistically with opioids to provide analgesic benefit at sub-therapeutic doses. Authors also suggested that “cannabis may be an efficacious tool” in the treatment of symptoms associated with opioid withdrawal.

They concluded: “The opioid overdose epidemic is arguably the worst public health crisis in U.S. history. … A continental crisis of this magnitude warrants the immediate implementation of novel strategies that prevent opioid misuse, overdose, and death. Growing pre-clinical and clinical evidence appears to support the use of cannabis for these purposes. The evidence summarized in this article demonstrates the potential cannabis has to ease opioid withdrawal symptoms, reduce opioid consumption, ameliorate opioid cravings, prevent opioid relapse, improve OUD treatment retention, and reduce overdose deaths.”

Separate clinical data published online last week in the journal Addiction reported that daily cannabis users undergoing therapy for opioid dependence are far more likely to complete their treatment regimen than are non-users


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Emerging evidence for cannabis’ role in opioid use disorder,” appears in Cannabis and Cannabinoid Research. NORML’s fact-sheet, “Relationship between marijuana and opioids,” is online.

Father of THC Dr. Raphael Mechoulam Keynotes CannX Oct 14-16 In Tel Aviv

ISRAEL: Dr. Raphael Mechoulam, Professor of Medicinal Chemistry at The Hebrew University of Jerusalem, Israel, and the man credited with first discovering and isolating THC will keynote the 3rd International Medical Cannabis Conference (CannX), October 14-16th in Tel Aviv.

Screenshot 2018-10-01 07.59.40

Speaking on The Plant Cannabinoids And The Endocannabinoid System — An Overview Of Research Over Five Decades, Dr. Mechoulam will set the stage for the two-day interactive science conference.  CannX was created as a interactive forum for top global leaders in all areas of medical cannabis to explore the latest scientific and clinical research, agricultural practices and innovation, and business opportunities in medical cannabis.

Screenshot 2018-10-01 07.24.56Joining Dr. Mechoulam in delivering keynote speeches will be Donald Abrams, Professor of Clinical Medicine at the University of California, Dr Kirsten R. Müller-Vahl Director of Tourette Syndrome Clinic at the Medical School of Hannover, Germany, and Prof. Michael Dixon Expert for the effects of Environmental on cannabis grow at School of Environmental Sciences, The University of Guelph, Canada.

IMG_1598

CannX will feature research on:

  • Dementia and Cannabis TreatmentUtilizing the “Entourage Effect” for the Alleviation of Sleep Disorder Symptoms
  • What Is Known about Marijuana’s Potential Utility in Treating Tourette Syndrome?
  • The Health Effects of Cannabis and Cannabinoids: Will Cannabis Cure Cancer?
  • The Latest Space Exploration Life Support Technology Finds Applications in Medical Cannabis Production
CannX 2018_banner_650x650Program Tracks: The scientific program includes three key areas of specialization and interest:
SCI: Innovations in Science and Medicine

Follow this track and explore the latest scientific and clinical research.

Benefit from it if you are:

✓  Scientific Researcher
✓  Medical Practitioner
✓  Medical Cannabis Organization

New Technologies, New Opportunities

Follow this track and get insight to the latest technologies and business opportunities in medical cannabis.

Benefit from it if you are:

✓  Investor & Analyst
✓ Consultant
✓  Lawyer & Accountant
✓  “Start-up” (& those looking to be)
✓  Journalist

AGR: Advanced Agriculture and Production

Follow this track and be up-to-date with the new agricultural practices and innovation.

Benefit from it if you are:

✓  Cannabis Growers
✓ Medical Cannabis Producers
✓  Plant breeders
✓ Agronomists
Pic 45
BIZ and AGR tracks are recommended for suppliers in any of the fields:
✓  Water Technology
✓  Transport & Logistics
✓  Equipment, Seed, Lighting, Soil Nutrient, Security Suppliers

CannX registration deadline is October 4register before October 3rd and save.